专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220267376A1 P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES 有权
公开(公告)号：US20220267376A1
公开(公告)日：2022-08-25
申请号：US17618751
申请日：2020-06-16
申请人： Tomi K. SAWYER , Pietro ARONICA , Christopher J. BROWN , Fernando J. FERRER , Charles W. JOHANNES , Srinivasaraghavan KANNAN , David P. LANE , Anthony W. PARTRIDGE , Yaw Sing TAN , Chandra S. VERMA , Tsz Ying YUEN , Merck Sharp & Dohme Corp. , Agency for Science, Technology and Research , MSD International GMBH (Singapore Branch)
发明人： Pietro Aronica , Christopher J. Brown , Fernando J. Ferrer , Charles W. Johannes , Srinivasaraghavan Kannan , David P. Lane , Anthony W. Partridge , Tomi K. Sawyer , Yaw Sing Tan , Chandra S. Verma , Tsz Ying Yuen
IPC分类号： C07K7/08 , A61K45/06 , C07K7/06 , A61P35/00
摘要： Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described. These all-D configuration α-amino acid peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.

2. 发明申请

US20190248879A1 ANTI-P53 ANTIBODIES 审中-公开
公开(公告)号：US20190248879A1
公开(公告)日：2019-08-15
申请号：US16342763
申请日：2017-10-17
申请人： Agency for Science, Technology and Research , Singapore Health Services Pte. Ltd. , National University of Singapore
发明人： Tr Kanaga Sabapathy , David P. Lane , Le-Ann Hwang , Xin Yu Koh , Liew Oi Wah
IPC分类号： C07K16/18 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/575 , A61P35/00 , C07K2317/24 , C07K2317/34
摘要： The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using said mutant p53 polypeptide as an immunogen wherein said polypeptide comprises: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of said antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses the use of antibodies for imaging and treatment of cancer.

3. 发明公开

US20230257457A1 ANTI-P53 ANTIBODIES 审中-公开
公开(公告)号：US20230257457A1
公开(公告)日：2023-08-17
申请号：US18172773
申请日：2023-02-22
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , SINGAPORE HEALTH SERVICES PTE. LTD. , NATIONAL UNIVERSITY OF SINGAPORE
发明人： Tr Kanaga Sabapathy , David P. Lane , Le-Ann Hwang , Xin Yu Koh , Liew Oi Wah
IPC分类号： C07K16/18 , A61P35/00 , A61K49/00 , A61K39/00
CPC分类号： C07K16/18 , A61P35/00 , A61K49/0058 , A61K39/00 , A61K2039/505 , C07K2317/34 , C07K2317/24 , A61K2039/552 , A61K2039/80 , A61K2039/575
摘要： The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using as an immunogen a peptide or polypeptide comprising: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration. Also provided are antibodies produced by such methods, and uses thereof.

4. 发明授权

US11319344B2 Non-membrane disruptive P53 activating stapled peptides 有权
公开(公告)号：US11319344B2
公开(公告)日：2022-05-03
申请号：US15550766
申请日：2016-02-15
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： Yaw Sing Tan , Christopher John Brown , Chandra S. Verma , Fernando Jose Ferrer Gago , David P. Lane , Thomas Joseph
IPC分类号： A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08 , A61K45/06 , A61P35/00 , A61K38/00
摘要： The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaa1EY-WXaa3LLXaa2, where Xaa1 is (R)-2-(7′-octenyl)alanine or derivative thereof, or is (R)-2-(4′-pentenyl)alanine or derivative thereof; and Xaa2 and Xaa3 are independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaa1EYW Xaa3LLXaa2ENXaa5, wherein Xaa1 and Xaa3 are any type of amino acid or modified amino acid; Xaa2 is S, or P, or (S)-2-(4′-pentenyl)alanine or a derivative of (S)-2-(4′-pentenyl)alanine; and wherein Xaa5 is F or Y.

5. 发明授权

US11613568B2 Anti-p53 antibodies 有权
公开(公告)号：US11613568B2
公开(公告)日：2023-03-28
申请号：US16342763
申请日：2017-10-17
申请人： Agency for Science, Technology and Research , Singapore Health Services Pte. Ltd. , National University of Singapore
发明人： Tr Kanaga Sabapathy , David P. Lane , Le-Ann Hwang , Xin Yu Koh , Liew Oi Wah
IPC分类号： C07K16/18 , A61P35/00 , A61K49/00 , A61K39/00
摘要： The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using the mutant p53 polypeptide as an immunogen wherein the polypeptide comprises: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of the antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses the use of antibodies for imaging and treatment of cancer.

6. 发明申请

US20110243968A1 THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER 有权
标题翻译： P53认证在再生医学，老化和癌症中的应用
公开(公告)号：US20110243968A1
公开(公告)日：2011-10-06
申请号：US12742250
申请日：2008-10-21
申请人： Curtis C. Harris , Kaori Fujita , Izumi Horikawa , Borivoj Vojtesek , Jean-Christophe Bourdon , David P. Lane
发明人： Curtis C. Harris , Kaori Fujita , Izumi Horikawa , Borivoj Vojtesek , Jean-Christophe Bourdon , David P. Lane
IPC分类号： A61K31/713 , C12N5/071 , C12N5/09 , A61K31/7088 , C12N15/85 , A61K48/00 , C07H21/02 , A61P43/00 , A61P35/00 , A61P37/06
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , A61K48/00 , C07K14/4746 , C12N5/0652 , C12N15/1135 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/141 , C12N2310/531
摘要： The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.
摘要翻译：本发明提供使用p53肿瘤抑制蛋白的同种型调节细胞衰老和细胞增殖的方法和组合物。通过调节细胞衰老和增殖，本发明的方法和组合物用于抑制癌细胞生长或产生用于组织再生的细胞群体。

7. 发明授权

US09785906B2 Content feedback in a multiple-owner content management system 有权
公开(公告)号：US09785906B2
公开(公告)日：2017-10-10
申请号：US13313316
申请日：2011-12-07
申请人： Gregory S. Reid , Timothy Ringo , David P. Lane , Elizabeth H. Lian , Daniel C. Farrell , Craig Fenton , Elise Shearing , Randy Bell , Sevasti Wong , Anthony Lingham , Audrey Forrester , Claudia Staubitz , Kevin Adams , Lesley Pickering , Paul Ritchie
发明人： Gregory S. Reid , Timothy Ringo , David P. Lane , Elizabeth H. Lian , Daniel C. Farrell , Craig Fenton , Elise Shearing , Randy Bell , Sevasti Wong , Anthony Lingham , Audrey Forrester , Claudia Staubitz , Kevin Adams , Lesley Pickering , Paul Ritchie
IPC分类号： G06Q10/00 , G06Q10/06 , G06Q10/10 , G06Q30/06 , G06Q50/18
CPC分类号： G06Q10/06398 , G06Q10/063 , G06Q10/06393 , G06Q10/10 , G06Q30/0601 , G06Q30/0641 , G06Q50/184
摘要： New functions for a contact center system include: testing user's comprehension of informational messages; capturing insight users having a KPI score above a threshold by having those users submit information on why they perform well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application and reference material that's context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system.

8. 发明授权

US07395499B2 Enforcing template completion when publishing to a content management system 有权
标题翻译：发布到内容管理系统时，强制模板完成
公开(公告)号：US07395499B2
公开(公告)日：2008-07-01
申请号：US10306026
申请日：2002-11-27
申请人： David P. Lane , Gregory S. Reid , Timothy A. Ringo , Elizabeth H. Lian , Daniel C. Farrell , Craig Fenton , Elise Clarke , Randy Bell , Sevasti Wong , Anthony Lingham , Audrey Forrester
发明人： David P. Lane , Gregory S. Reid , Timothy A. Ringo , Elizabeth H. Lian , Daniel C. Farrell , Craig Fenton , Elise Clarke , Randy Bell , Sevasti Wong , Anthony Lingham , Audrey Forrester
IPC分类号： G06F17/00
CPC分类号： G06F17/30899
摘要： New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.
摘要翻译：联络中心系统的新功能包括：通过测验测试用户对信息消息的理解; 通过让这些用户提交关于他们为什么表现如此出色的信息，获取KPI得分高于阈值的上级用户的洞察力; 通过基于新近度和频率周期性地重新排列解决方案来动态地排序问题的解决方案; 集成信息供联络中心代表在线与客户联系以供在线使用时使用; 将内容项目存储在电信行业分类中; 将内容项目的用户反馈引导到该内容的正确的所有者/管理者; 使用解决方案分类法传达解决方案信息; 显示具有CRM应用程序的双重信息系统以及适合上下文的参考资料; 在创建要发布的内容项时强制完成一组模板; 确保一组内容项目的模板在发布之前已经完成; 并使用连续的搜索功能在联络中心系统门户中进行搜索。

9. 发明授权

US06613878B1 PCNA binding substance 失效
标题翻译： PCNA结合物质
公开(公告)号：US06613878B1
公开(公告)日：2003-09-02
申请号：US08945645
申请日：1998-07-31
申请人： Lynne S. Cox , David P. Lane , Emma Warbrick , David M. Glover
发明人： Lynne S. Cox , David P. Lane , Emma Warbrick , David M. Glover
IPC分类号： A61K3808
CPC分类号： C12N9/22 , A61K38/00 , C07K14/4738
摘要： Fragments of Fen1 that interact with PCNA are disclosed, together with the use of such fragments or mimetics of Fen1 in methods of screening for compounds useful in treating disorders in which PCNA is implicated. In particular, substances which have the property of binding to PCNA are disclosed, said substances comprising: (i) a fragment of the Fen1 protein containing a peptide of 89 amino acids from the C-terminal region or an active portion thereof; or, (ii) a fragment of the Fen1 protein containing the sequence motif QGRLDxFF; or, (iii) a functional mimetic of said protein fragments; where “x” is preferably the selected form the amino acids S, D or G.
摘要翻译：公开了与PCNA相互作用的Fen1片段，以及在筛选可用于治疗PCNA所涉及的疾病的化合物的方法中使用Fen1的这种片段或模拟物。特别地，公开了具有与PCNA结合的性质的物质，所述物质包括：（i）含有C末端区域或其活性部分的89个氨基酸的肽的Fen1蛋白的片段; 或（ii）含有序列基序QGRLDxFF的Fen1蛋白的片段; 或（iii）所述蛋白质片段的功能模拟物;其中“x”优选为所选形式的氨基酸S，D或G.

10. 发明授权

US08575121B2 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer 有权
标题翻译： p53异构体在再生医学，衰老和癌症中的治疗应用
公开(公告)号：US08575121B2
公开(公告)日：2013-11-05
申请号：US12742250
申请日：2008-10-21
申请人： Curtis C. Harris , Kaori Fujita , Izumi Horikawa , Borivoj Vojtesek , Jean-Christophe Bourdon , David P. Lane
发明人： Curtis C. Harris , Kaori Fujita , Izumi Horikawa , Borivoj Vojtesek , Jean-Christophe Bourdon , David P. Lane
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/711 , A61K31/713 , A61K48/00 , C07K14/4746 , C12N5/0652 , C12N15/1135 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/141 , C12N2310/531
摘要： The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.
摘要翻译：本发明提供使用p53肿瘤抑制蛋白的同种型调节细胞衰老和细胞增殖的方法和组合物。通过调节细胞衰老和增殖，本发明的方法和组合物用于抑制癌细胞生长或产生用于组织再生的细胞群体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式